ABCL: AbCellera Biologics Inc. Price Target Chart
AbCellera Biologics (ABCL) minimizes losses from failed tests through hundreds of contracts with global pharma leaders. This price action reflects the operation of an AI system that assists partners in creating unique antibodies. The current consensus is 17.99. The company is currently expecting new profit cycles, as previous royalties have declined and platform development relies on the later stages of project implementation.
Analytical breakdowns for AbCellera Biologics Inc. (ABCL)
- stock value and consensus price forecast:
- market capitalization information:
- issuer book value statistics:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity AbCellera Biologics|ABCL - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital AbCellera Biologics Inc|ABCL - Company Aggregate Debts|Debts to Book Capitalization AbCellera Corp|ABCL - Company Long-Term Debt|Company Short-Term Loans and Borrowings AbCellera|Quick Liquidity Indicator abcellera.com
- business earnings and investment ratios data:
ABCL - Net Profit|Projected Future Earnings AbCellera Biologics|ABCL - Price to Earnings Ratio|Future Price to Earnings Multiple AbCellera Biologics|ABCL - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio AbCellera Corp|ABCL - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months AbCellera|ABCL - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months abcellera.com|ABCL - Net earnings per share growth this year|Earnings growth forecast for next year AbCellera Biologics
General company analysis:ABCL AbCellera Bio
Defensive assets are selected based on the criterion of low correlation with market cycles. AbCellera Biologics (ABCL) meets this requirement, as its revenues depend on the success of clinical trials and royalties rather than macroeconomics. The arithmetic mean of expert price targets determines the fair value equilibrium point. By analyzing changes in the average target price, an investor can track the dynamics of market expectations. This allows for the timely detection of a trend reversal when fundamental drivers shift.
Competitors of AbCellera Biologics
Analyst Consensus Forecast argenx.com (ARGX)|Analyst Consensus Forecast BNTX (BioNTech)|Abivax SA - Price Target Chart|ADMA Bio - Analyst Consensus Forecast|Protagonist Corp (PTGX) - Consensus Target|Immunovant, Inc. (IMVT) - Price Target Chart|KNSA (kiniksa.com) - Price Target Chart|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|Tourmaline Corp (TRML) - Price Target Chart|Consensus Target Precigen Corp|PHAR (Pharming Group N.V.) - Analyst Consensus Forecast|Analyst Consensus Forecast nektar.com|Consensus Target UPB (Upstream Bio)|ZBIO (Zenas Bio) - Fair Value Consensus|Analyst Consensus Forecast IMNM (Immunome Corp)|Analyst Median Target Gossamer Bio Corp. (GOSS)|KALV - Price Target Chart|septerna.com (SEPN) - Consensus Target|Pieris Pharmaceuticals, Inc. (PVLA) - Price Target Chart|Consensus Target Savara Inc|Consensus Target RIGL|Analyst Consensus Forecast AnaptysBio Inc.|Price Target Chart Astria Therapeutics (ATXS)|engene.com - Broker Consensus Forecast|Analyst Consensus Forecast RAPT (RAPT Therapeutics, Inc.)|Aerovate Therapeutics, Inc. (JBIO) - Average Forecast Price|Aclaris - Analyst Consensus Forecast|KYTX - Analyst Consensus Forecast|TLSA: Analyst Consensus Forecast|CABA (cabalettabio.com) - Price Target Chart|VTYX (Ventyx Biosciences, Inc.) - Analyst Consensus Forecast|Consensus Target Theratechnologies, Inc. (THTX)|Analyst Consensus Forecast AVTX|ELDN - Average Forecast Price|Price Target Chart Agenus AGEN|climbbio.com - Price Target Chart|ZURA - Price Target Chart|ATYR: Price Target Chart|ADAG: Analyst Consensus Forecast|Average Forecast Price Ikena Oncology (IMA)|Price Target Chart Shattuck Labs Inc|EQ: Fair Value Consensus|Analyst Consensus Forecast CNTB|Analyst Consensus Forecast immunic-therapeutics.com (IMUX)|Atara Bio - Consensus Target|Fair Value Consensus IFRX|X4 Pharmaceuticals - Analyst Consensus Forecast|ACET: Price Target Chart|CELU: Analyst Consensus Forecast|INMB - Analyst Median Target|Price Target Chart Barinthus Bio|Average Forecast Price Kezar Life Sciences Inc KZR|Price Target Chart SAB Biotherapeutics (SABS)|Price Target Chart AKTX (akaritx.com)|Price Target Chart Enlivex Therapeutics Ltd. ENLV|Q32 Bio Inc (QTTB) - Average Forecast Price|GeoVax Labs Inc - Analyst Consensus Forecast|Analyst Target Range Edesa Biotech Corp (EDSA)|IBIO: Analyst Consensus Forecast|CARM - Analyst Median Target|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Consensus Target Bolt Bio (BOLT)|Price Target Chart HCW Biologics Inc. (HCWB)|Analyst Median Target aptevotherapeutics.com|Analyst Consensus Forecast AIM (AIM ImmunoTech)|Analyst Consensus Forecast Aditxt Inc. ADTX|GRI Bio - Analyst Consensus Forecast|XRTX: Price Target Chart|HIND: Analyst Consensus Forecast|Consensus Target Revelation Biosciences Corp|Price Target Chart Indaptus Therapeutics|Price Target Chart SCNI|Price Target Chart CalciMedica, Inc. (CALI)|AFMD: Forecast Levels Chart|Analyst Consensus Forecast ALLK (Allakos)|Fair Value Consensus HOOK|IGM Bio - Analyst Consensus Forecast|ITOS - Analyst Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|TC BioPharm (Holdings) Plc - Fair Value Consensus|Price Target Chart Third Harmonic Bio, Inc
